mif

MIF-IN-2 is a heterocyclic macrophage migration inhibitory factor (MIF) inhibitor with anticancer activity for the study of cancer and autoimmune disorders.13460-73-86-5

MIF098, a macrophage migration inhibitory factor (MIF) antagonist, inhibits pulmonary hypertension associated with SLE and the proliferation and migration of pulmonary arterial smooth muscle cells (PASMC). MIF098 may also be used to study idiopathic pulmonary hypertension.

The MIF Antagonist IV, RDR 03785 controls the biological activity of MIF. This small molecule/inhibitor is primarily used for Cell Structure applications.

(±)-CPSI-1306 (2-(3-(2,4-Difluorophenyl)-4,5-dihydroisoxazol-5-yl)-1-morpholinoethan-1-one) is a macrophage migration inhibitory factor (MIF) antagonist and can be used in studies about non-insulin-dependent diabetes mellitus (NIDDM) and the prevention of the deleterious cutaneous effects of acute and chronic UVB exposure.

Iguratimod (T614) is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.

MIF-IN-1 (compound 14) is a potent inhibitor of macrophage migration inhibitory factor (MIF) with a pIC50 of 6.87, targeting a proinflammatory cytokine linked to various diseases, including neurodegenerative disorders [1].

MIF-IN-5 (compound 1d) is a potent, reversible competitive inhibitor of macrophage migration inhibitory factor (MIF), with an IC₅₀ of 4.8 μM and a Ki of 3.3 μM [1].

MIF-IN-6 (compound 2d) is an effective inhibitor of macrophage migration inhibitory factor (MIF), with an IC50 of 1.4 μM and a Ki value of 0.96 μM. It effectively reduces MIF-induced ERK phosphorylation and impedes A549 cell proliferation [1].

MIF-IN-3 is an inhibitor of migration inhibitory factor (MIF), which can be used in the study of immunoinflammation-related diseases.

MIF-IN-4 hydrochloride is a potent inhibitor of macrophage mobility inhibitory factor (MIF) with pIC50 values ranging from 5.01-6. Where MIF was originally discovered as a cytokine in the process of inhibiting macrophage migration.

MIF degrader MD13 is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active siteMIF degrader MD13. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.

4-IPP (4-Iodo-6-phenylpyrimidine) is an irreversible inhibitor of macrophage migration inhibitory factor (MIF).

Epoxyazadiradione is an extract from Neem (Azadirachta indica) plant and may induce mitochondrial apoptosis and inhibition of NF-kB in human cervical cancer cells.

Boc-MIF-1-Am (compound 2) acts as a human dopamine D2 receptor enhancer with an EC50 value of 17.82 nM and is a bioconjugate of melanostatin (MIF-1) and amantadine. At a concentration of 200 μM, Boc-MIF-1-Am exhibits slight neurotoxicity in SH-SY5Y cells.

MIF-1 TFA (Melanostatin), an intrinsic brain peptide, serves as a powerful allosteric modulator of the dopamine receptor. It plays a crucial role in regulating melanin production and modifies the analgesic efficacy by inhibiting the opioid receptor's effects. Significantly, MIF-1 TFA can cross the blood-brain barrier (BBB) directly, facilitating its access from the bloodstream to the central nervous system (CNS) [1] [2] [3].

Tyr-W-MIF-1, an opioid tetrapeptide, exhibits both opiate and antiopiate activities, and has been demonstrated to induce analgesia [1] [2] [5].

Amifostine (Ethyol) anhydrous is a cytoprotective agent, acts as a free radical scavenging activity.

Mifamurtide is a drug against osteosarcoma, is an immunomodulator with antitumor effects.

P32/98 hemifumarate is a dipeptidyl peptidase IV (DPP4) inhibitor with hypoglycemic properties that improves insulin sensitivity and β-cell responsiveness in the Zucker diabetic rat model, and may be useful in studies of type 2 diabetes and colitis.

Fispemifene (HM-101) is an estrogen receptor modulator (SERM) used to treat genitourinary syndromes and vaginal atrophy.

Panomifene HCl is a selective anti-estrogenic compound with antitumor activity for the treatment of breast cancer.

Panomifene TFA(GYKl13504 TFA) is a small molecule antagonist of ERs with anticancer activity that can be used to study breast cancer and musculoskeletal diseases.

Alamifovir PM is an analogue of Alamifovir, an HBV-specific antiviral compound.

Mifentidine (DA 4577) is an orally available H2 receptor antagonist for the study of gastric emptying and experimental gastric and duodenal ulcers.